CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis

被引:84
作者
Muta, H [1 ]
Boise, LH [1 ]
Fang, L [1 ]
Podack, ER [1 ]
机构
[1] Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA
关键词
D O I
10.4049/jimmunol.165.9.5105
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Although CD30 has long been recognized as an important marker on many lymphomas of diverse origin and as activation molecule on B cells and T cells, its primary function has remained obscure. We now report that CD30 signals may serve to inhibit effector cell activity by integrating gene expression changes of several pathways important for cytotoxic NK and T cell effector function. In the large granular lymphoma line YT, CD30 signals down-regulate the expression of cytotoxic effector molecules, Fas ligand, perforin, granzyme B, and abrogate cytotoxicity, c-myc, a regulator of proliferation and an upstream regulator of Fas ligand expression, is completely suppressed by CD30, Furthermore, CD30 signals strongly induce CCR7, suggesting a role for CD30 signals in the homing of lymphocytes to lymph nodes, The up-regulation of Fas, death receptor 3, and TNF-related apoptosis-inducing ligand by CD30 indicates an increase in susceptibility to apoptotic signals whereas up-regulation of TNFR-associated factor 1 and cellular inhibitor of apoptosis 2 protect cells from certain types of apoptosis, Using gene microarrays, 750 gene products were induced and 90 gene products were suppressed >2-fold by CD30 signals, Signals emanating from CD30 use both TNFR-associated factor 2-dependent and -independent pathways. The integration of CD30 signals in a lymphoma line suggests that CD30 can down-modulate lymphocyte effector function and proliferation while directing the cells to lymph nodes and increasing their susceptibility to certain apoptotic signals. These studies may provide a molecular mechanism for the recently observed CD30-mediated suppression of CTL activity in vivo in a diabetes model.
引用
收藏
页码:5105 / 5111
页数:7
相关论文
共 35 条
[1]  
ALZONA M, 1994, J IMMUNOL, V153, P2861
[2]   Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice [J].
Amakawa, R ;
Hakem, A ;
Kundig, TM ;
Matsuyama, T ;
Simard, JJL ;
Timms, E ;
Wakeham, A ;
Mittruecker, HW ;
Griesser, H ;
Takimoto, H ;
Schmits, R ;
Shahinian, A ;
Ohashi, PS ;
Penninger, JM ;
Mak, TW .
CELL, 1996, 84 (04) :551-562
[3]  
AZUMA M, 1992, J IMMUNOL, V149, P1115
[4]  
BOWEN MA, 1993, J IMMUNOL, V151, P5896
[5]  
Bowen MA, 1996, J IMMUNOL, V156, P442
[6]   In vitro cell death of activated lymphocytes in Omenn's syndrome [J].
Brugnoni, D ;
Airo, P ;
Facchetti, F ;
Blanzuoli, L ;
Ugazio, AG ;
Cattaneo, R ;
Notarangelo, LD .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1997, 27 (11) :2765-2773
[7]   CD30 in normal and neoplastic cells [J].
Chiarle, R ;
Podda, A ;
Prolla, G ;
Gong, J ;
Thorbecke, GJ ;
Inghirami, G .
CLINICAL IMMUNOLOGY, 1999, 90 (02) :157-164
[8]  
Chiarle R, 1999, J IMMUNOL, V163, P194
[9]   Induction of nuclear factor kappa B by the CD30 receptor is mediated by TRAF1 and TRAF2 [J].
Duckett, CS ;
Gedrich, RW ;
Gilfillan, MC ;
Thompson, CB .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (03) :1535-1542
[10]   CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival [J].
Duckett, CS ;
Thompson, CB .
GENES & DEVELOPMENT, 1997, 11 (21) :2810-2821